The recent 4th of July holiday in the United States served as a simultaneous reminder of both the visual beauty and the ocular hazards associated with fireworks displays. There is no doubt that fireworks can be stunning, drawing the eyes to them immediately.
A recent paper quantified ocular injuries as a result of fireworks that were treated at level 1 trauma centers in the United States during an 11-year period.1 Overall, there were 327 patients treated for injuries from fireworks, and nearly one-third of these were ocular in nature. Of patients who had ocular injuries, 28% required surgery, and 58% of those who had ruptured globes ended up having no light perception in the affected eye.
Although fireworks are indeed a thing of beauty, it is important to remember the hazards associated with them that impact our patients.
1. Chang IT, Prendes MA, Tarbet KJ, Amadi AJ, Chang SH, Shaftel SS. Ocular injuries from fireworks: the 11-year experience of a US level I trauma center. Eye (Lond). 2016 Oct;30:1324-1330.
Jason J. Nichols, OD, MPH, PhD
VTI Adds OOGP as Authorized Distribution Partner
Visioneering Technologies, Inc. (VTI) has added OOGP, a distributor of optical products in the United States, as the company’s latest Authorized Distributor partner for the NaturalVue (etafilcon A) Brand 1-Day Contact Lenses.
ABB Optical Group and Paragon Vision Sciences Announce Fourth Annual Optometry Student Challenge
ABB Optical Group, in partnership with Paragon Vision Sciences, is accepting abstracts for its 2018-2019 Optometry Student Challenge. The Optometry Student Challenge will award travel grants of $1,500 each to three third- or fourth-year students to attend the 2019 Global Specialty Lens Symposium (being held Jan. 24 to 27, 2019 in Las Vegas) and present a scientific poster on a topic related to contact lenses. Conference registration costs will be covered for the three winners as well.
Third- and fourth-year students who are interested in participating must register by July 31. Registered students must then submit an abstract on their proposed poster topic by Oct. 15. Abstracts must focus on study projects or student-based case histories related to contact lenses. Topics can include, but are not limited to, contact lens applications for presbyopia, keratoconus, corneal topography, post-penetrating keratoplasty or related irregular corneal surface, myopia control, lens care/solutions, and orthokeratology. Abstracts will be judged in two categories: case study report and research. Five finalists will be selected and notified by Oct. 31.
The finalists will then be required to convert their abstracts into scientific posters for further judging. The posters must be submitted in digital, PDF format to ABB Optical Group no later than Nov. 21. Judges will then select the top three posters by Dec. 1.
The lead authors of the top three posters will be awarded travel grants of $1,500 each to attend the symposium and present their posters. Additionally, the two runners-up will receive honorable mention prizes of $250 each.
SynergEyes Appoints Bob Ferrigno CEO
The SynergEyes, Inc. board of directors appointed Bob Ferrigno as CEO, effective June 27, 2018. Ferrigno joined SynergEyes in 2015 and has led the sales and marketing efforts in expanding the company from a hybrid contact lens company to a specialty contact lens company.
Prior to joining SynergEyes, he served as the president of North America for CooperVision. Before that, he held executive and general management positions with Becton Dickinson, a global medical technology company, for 32 years, managing key areas including sales, marketing, international operations, and global research and development.
Ferrigno is succeeding James Kirchner, OD, who will assume the role of president emeritus. Dr. Kirchner will continue to develop and foster relationships within the U.S. eyecare community, be involved in new product development, and advocate for SynergEyes contact lenses in the areas of myopia management, presbyopia, and other eye conditions.
Dr. Millicent Knight to Join Essilor of America
Essilor of America has announced that Millicent Knight, OD, will be joining the company later this summer as senior vice president, customer development group and member of the leadership team, reporting to Rick Gadd, incoming president, Essilor of America. In this role, Dr. Knight will be responsible for Essilor of America’s professional relations, communications and eyecare professional and sales training efforts.
Prior to Essilor, she was vice president of professional affairs, North America at Johnson & Johnson Vision Care, Inc. While there, she served on the North American leadership team. Dr. Knight has also consulted for eyecare and health and wellness companies, conducted contact lens and solutions office clinical trials, and lectured on a wide variety of topics including contact lenses, leadership, cultural sensitivity, eye and systemic health, and business and entrepreneurship.
New Scleral Lens Care Kit from Bausch + Lomb
Following the recent launch of the Boston scleral lens case, Bausch + Lomb’s Specialty Vision Products business is launching scleral lens care kits to provide patients with products to help apply, remove, and maintain their scleral lenses.
The kit provides the components needed for care and application of scleral lenses, all in a convenient zipper bag, according to the company. Contents include the Boston scleral lens case, a magnifying mirror, application and removal tools, and ScleralFil Preservative Free Saline Solution. The kit is available either with or without a 3.5mL bottle of Boston Simplus Multi-Action Solution.
The kit will be available to eyecare professionals and patients for purchase exclusively on www.bauschSVPstore.com.
Katena Products Acquires Blink Medical Ltd.
Katena Products, a provider of precision ophthalmic instruments, biologics, and devices to hospitals, surgical centers, and ophthalmic and optometric offices, announced the purchase of Blink Medical Ltd, a United Kingdom-based provider of primarily single-use ophthalmic instruments. Founded in 2004, Blink Medical currently distributes its products within Europe and the Middle East, which will provide Katena with a physical presence in Europe for its products, according to the companies.
Myopia Profile Website Updated
Drs. Kate and Paul Gifford have updated the Myopia Profile website. The updated site will include five learning portals that cover the following topics: understanding the fundamentals, getting started in practice, understanding the options, expanding your clinical skills, and staying at the cutting edge. In addition, all of the topics discussed in the Myopia Profile Facebook group, and information that practitioners have heard in lectures, will be collated into one place and thoroughly referenced. This information will be added to the relevant portals. These blogs are designed to be practical, with topics such as contact lens safety in kids, why binocular vision matters in myopia, understanding efficacy, and clinical decision-making trees. The site also offers podcasts and news.
Parents will also have the ability to link to the “My Kids Vision” website (https://medium.com/mykidsvision), which also features a new blog and new Facebook page.
MPOD Measurement Earns American Medical Association CPT III Code
EyePromise announced that macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT codes are used for data collection and tracking for products or services involved in planned or ongoing research to help researchers substantiate widespread usage and efficacy. The code is effective for dates of service on or after July 1, 2018.
Colgate-Palmolive Co. to Purchase Minority Stake in Hubble
Colgate-Palmolive Co. is looking to invest in Hubble, a direct-to-consumer online contact lens subscription seller. Through the agreement, Colgate would utilize Hubble’s online sales and distribution systems to sell its oral care products to start.
Reports point to Colgate purchasing a minority stake in Hubble, but this has not yet been confirmed. And, while financial details of the deal were not disclosed, it’s reported that the two companies will share revenue from the venture.
Custom Stable Cup Winners Take Home Three Scholarship Awards
Valley Contax held the Custom Stable Cup Challenge at Optometry’s Meeting 2018 in Denver this past June. Current optometry students and alumni were encouraged to participate by visiting the company’s booth where they partnered up and applied the Custom Stable lens with sodium fluorescein. More than 100 students and alumni from many different schools of optometry participated. First place was awarded to Southern College of Optometry, which received two $500 scholarships and the Custom Stable Cup. The second place winner was Midwestern University Arizona College of Optometry, which was awarded a $500 scholarship. Valley Contax, Menicon, Contamac, Optovue, and TelScreen were all contributing sponsors along with special support from the American Optometric Student Association.
Allergan plc launched Refresh Repair Lubricant Eye Drops, a new over-the-counter (OTC) artificial tear formulation. Refresh Repair is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants. Refresh Repair tears are designed to repair and protect the eyes from the harmful effects of dry eye and to improve clarity of vision, according to Allergan. In addition, Refresh Repair is safe to use with contact lenses.
AOCLE Holds Annual Workshop
The Association of Optometric Contact Lens Educators (AOCLE) held its annual workshop at University of the Incarnate Word Rosenberg School of Optometry in San Antonio in early June. More than 50 educators and 28 industry representatives attended the meeting, which featured a theme of “Look, Learn, Teach.” Topics included interprofessional education for optometrists, test writing, and ways to communicate more effectively.
In addition, new officers were elected: Dr. Katie Clore, chair; Dr. Julie DeKinder, vice chair; Dr. Beth Kinoshita, secretary; Dr. Latricia Pack, treasurer; and Dr. Susan Kovacich, immediate past chair.
The George Mertz New Educator Travel Award was presented to Dr. Nekima Williams from Rosenberg School of Optometry, and the inaugural Dr. Harue J. Marsden New Educator Travel Award was presented to Dr. Kate A. McClure from The Ohio State University College of Optometry. These awards provide travel funds to the AOCLE workshop to young educators who are making an impact in contact lens education at their respective institutions. Dr. Bruce W. Morgan, from Michigan College of Optometry, received the Lester E. Janoff Memorial Award, which is given to an optometric educator who has demonstrated excellence in contact lens education, research, and publications and who has been active in the AOCLE.
EzContacts.com Now Offers Online Vision Prescriptions Powered by Opternative
Opternative, Inc. announced that it has partnered with EzContacts to provide access to online prescription renewal technology on the company’s online eyewear site, EzContacts.com.
GSLS Accepting Free Paper and Poster Submissions
Free paper and poster topics should include new and innovative concepts on all aspects of contact lenses (such as materials, designs, lens care) in addition to related topics such as corneal and ocular surface disease, diagnosis and treatment approaches, and practice management.
Abstracts for free papers and posters will be accepted until Aug. 31, 2018 at 11:59 pm Eastern Standard Time (EST) and must be submitted online.
The poster competition will be judged in two categories: Clinical and Research. Learn More
Are you measuring tear osmolarity in clinical practice?
This image shows a scleral lens over a corneal patch graft in a case of severe exposure keratopathy. The lens vault was modified to ensure enough clearance over the patch, even after lens settling. The lens haptics were modified to eliminate any possibility of lens suction. The final scleral lens design provided this patient with 20/20 vision and great comfort, while supporting the ocular surface.
We thank Dr. Sotomayor for this image and welcome photo submissions from our other readers! It is easy to submit a photo for consideration for publishing in Contact Lenses Today. Simply visit http://www.cltoday.com/upload/upload.aspx to upload your image. Please include a detailed explanation of the photo and your full name, degree or title, and city/state/country.
S. Barry Eiden, OD
A Roadmap Toward a Myopia Management Standard of Care
Many studies regarding the management of myopia progression (especially with contact lenses) have been discussed in this column over the past few years, emphasizing the need for more evidence-based data to support the need and efficacy of such treatments. The one thing missing, however, is standardization that will lead to the establishment of standards of care in this area.
An article was recently published that reviewed the outcomes of an interprofessional workshop that included input from professional organizations and the U.S. Food and Drug Administration (FDA) regarding the most appropriate ways to design clinical trials in the myopia management space.1 The authors stated: “The prevalence of myopia is high and increasing. Approximately 5 billion people around the world are expected to be myopic by the year 2050. Methods to slow the progression of myopia and therefore potentially decrease the associated sight-threatening complications have been the subject of a number of investigations.” A workshop—sponsored by the FDA Center for Devices and Radiological Health, the American Academy of Ophthalmology, the American Academy of Optometry, the American Association for Pediatric Ophthalmology and Strabismus, the American Optometric Association, the American Society of Cataract and Refractive Surgery, and the Contact Lens Association of Ophthalmologists, Inc.—convened myopia experts from around the world to discuss principles to consider in the design of clinical trials investigating the effectiveness and safety of myopia control devices.
The article also noted that experts discussed parameters such as study endpoints, duration, enrollment criteria, patient-reported outcomes, recruitment, and retention. The authors noted that discussions among the experts, the FDA, and audience members should help to facilitate the development and evaluation of reasonably safe and effective myopia control devices.
This is a critical first step toward standardization of clinical research and care in the management of progressive myopia. Those who are interested in this topic (and most of us in eye care should be) should read this report.
1. Walline JJ, Robboy MW, Hilmantel G, et al. Food and Drug Administration, American Academy of Ophthalmology, American Academy of Optometry, American Association for Pediatric Ophthalmology and Strabismus, American Optometric Association, American Society of Cataract and Refractive Surgery, and Contact Lens Association of Ophthalmologists Co-Sponsored Workshop: Controlling the Progression of Myopia: Contact Lenses and Future Medical Devices. Eye Contact Lens. 2018 Jul;44:205-211.
OCULAR SURFACE UPDATE
Katherine M. Mastrota, MS, OD
A number of years ago, the adverse effects of the preservative thimerosal to the corneal surface were a hot topic. Similarly, benzalkonium chloride (BAK) has been of some concern to the ocular surface. BAK is found not only in many ocular therapeutic compounds, but also in many eye cosmetics.
Cosmetic products—such as mascara, eye shadow, eyeliner, and eye makeup remover—are used extensively to highlight the eyes or clean the eyelids and typically contain preservatives to prevent microbial growth. These include BAK and formaldehyde (FA)-releasing preservatives.
A recent investigation analyzed the influence of BAK and FA on the morphology, survival, and proliferation and signaling ability of immortalized human meibomian gland, corneal, and conjunctival epithelial cells.1
Not surprisingly, the authors found that BAK and FA cause dose-dependent changes in the morphology, survival, proliferation, and cell growth signaling pathways of these cell sets. Many of the concentrations tested induced cell atrophy, poor adherence, decreased proliferation, and death. These investigators conclude that these results support the hypothesis that cosmetic preservatives, BAK and FA, exert many toxic effects on cells of the ocular surface and adnexa.
Perhaps eyecare practitioners should include an additional query on their Dry Eye Questionnaire: List the cosmetic products that you use on your eyelids and around your eye.
1. Chen X, Sullivan DA, Sullivan AG, Kam WR, Liu Y. Toxicity of cosmetic preservatives on human ocular surface and adnexal cells. Exp Eye Res. 2018 May;170:188-197.
Evaluation of Long-Term Silicone Hydrogel Use on Ocular Surface Inflammation and Tear Function in Patients With and Without Meibomian Gland Dysfunction
The purpose of this study was to determine whether silicone hydrogel (SiHy) contact lens (CL) use, in patients who had and did not have meibomian gland dysfunction (MGD), promotes ocular surface inflammation.
This cross-sectional, single-center study included subjects wearing SiHy CLs for at least six months who also had coexisting MGD (group 1, n = 20), SiHy CL users who did not have MGD (group 2, n = 20), patients who had MGD but did not use CLs (group 3, n = 20), and healthy CL-naive individuals who have no known systemic or ocular diseases (group 4, n = 20). All subjects underwent tear function tests consisting of tear breakup time (TBUT), ocular surface staining, Schirmer’s test, and the Ocular Surface Disease Index (OSDI) questionnaire as well as determination of tear IL-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, IFN-α, IFN-γ, TNF-α, granulocyte-macrophage colony-stimulating factor, IP-10, monokine induced by gamma interferon, RANTES (regulated on activation, normal T cell expressed and secreted), eotaxin, MIP-1α, MIP-1β, and MCP-1 levels using Luminex multicytokine immunobead assay. Intergroup comparisons were made using one-way analysis of variance or Kruskal-Wallis test.
The TBUT was lower (P = 0.048) and ocular surface staining as well as OSDI scores (P = 0.032 and P = 0.001, respectively) were higher in group 1 but not in groups 2 or 3 when compared with those in the control group. Tear cytokine levels were similar across all groups. None of the tear cytokine levels were elevated in CL wearers (groups 1 and 2) or those who have MGD (groups 1 and 3) as compared to those in control subjects.
The authors concluded that SiHy contact lens use in patients who have concomitant MGD is not associated with cytokine-driven ocular surface inflammation, but it may impact tear function, leading to dry eye symptoms.
Yucekul B, Mocan MC, Kocabeyoglu S, Tan C, Irkec M. Evaluation of Long-Term Silicone Hydrogel Use on Ocular Surface Inflammation and Tear Function in Patients With and Without Meibomian Gland Dysfunction. Eye Contact Lens. 2018 Jun 25. [Epub ahead of print]